

# Lesbian / Gay Health

## AIDS and HIV Related Research

The National Institutes of Health (NIH) has provided national and international leadership in the fight against AIDS. Much of this effort depends on the ability of NIH to recruit patients infected with HIV and other volunteers for inpatient and outpatient studies of new drugs and vaccines. In order to recruit subjects, it is vitally important that information be available to the community.

Following is an updated list of studies for which the NIH is currently recruiting. Of special urgency are studies involving AZT and interferon which have both been in the news recently because of remarkable new developments. Much more needs to be learned about how to use them, however, and how to use potentially less toxic alternatives such as AZDU. Please be aware that after the initial screening visit, travel costs and medical care associated with these studies are free.

### HIV Infection

**Alpha Interferon/IL2-** Patients with HIV infection and at least 200 CD4/mm<sup>3</sup> are sought for a phase I trial of alpha interferon in combination with interleukin-2. Contact: Dianne Lee, RN (301)496-7196.

**AZT/Interferon 3 Arm Study-** AZT vs. AZT + Alpha interferon vs. Alpha interferon- This 3-arm, randomized, unblinded study seeks HIV-infected persons with a CD4 count of at least 500/mm<sup>3</sup> for a study comparing the efficacy of each of the 3 treatments. Contact: Victoria Davey, RN (301)496-7196.

**AZT/IL2-** Patients with HIV infection and at least 200 CD4 cells/mm<sup>3</sup> are sought for a phase I trial of AZT in combination with interleukin-2. Contact: Dianne Lee, RN (301)496-7196.

**GM-CSF/AZT/Alpha Interferon-** This study is designed to evaluate the safety, toxicity and efficacy of giving granulocyte-macrophage colony stimulating factor in combination with AZT and Interferon in

HIV infected persons with CD4 Counts of 200-500/mm<sup>3</sup>. Contact: Victoria Davey, RN (301)496-7196

**Azdu-** For the first human trials of 3'Azido-2',3'-dideoxyuridine (Azdu), patients with CD4 counts between 200 and 400/mm<sup>3</sup> are sought. Contact: Dianne Lee, RN (301)496-7196.

**AS-101 and AZT-** This phase I trial designed to obtain toxicity and preliminary data of AS-101 and AZT seeks HIV-infected persons able to tolerate AZT (or have no prior exposure to it) and with CD4 counts of <200/mm<sup>3</sup> or <20% lymphocytes. Contact: Debbie Ogata-Arakaki, RN (301)496-9565.

**Bronchoscopy Study-** This is a diagnostic study to evaluate the lung tissue and pulmonary status of persons who are HIV infected. Contact: Debbie Ogata-Arakaki, RN (301)496-9565.

### Normal Volunteers

**Vaccine (gp160)-** This is a phase I trial of an AIDS vaccine, recombinant HIV-envelope protein (gp 160). We are seeking healthy men who are HIV antibody negative to participate in this study. Contact: Margaret Easter, RN (301)496-7196.

### Pneumocystis Pneumonia

**Piritrexim-** This is a study designed to evaluate the toxicity and efficacy of oral piritrexim and leucovorin for therapy of PCP untreated for the current episode. Contact: Donna O'Neill, RN (301)496-9565.

**PCP Prophylaxis-** This is a phase I/II study designed to evaluate the toxicity and tolerance of weekly dapsone or dapsone/pyrimethamine in HIV-infected persons with prior history of PCP or who have less than 250/mm<sup>3</sup> CD4 cells. Contact: Debbie Ogata-Arakaki, RN (301)496-9565.

(Continued on page 8)

For confidential  
**AIDS**  
Information



Call

**1-800-882-AIDS**

**Join OITM !**

**Come to our Open House**

Friday, Oct 6th  
7:30-9:30 pm  
30 Elmwood Ave,  
Burlington  
(Above VT CARES)



**BARBARA Du BOIS**

PhD

Psychotherapy

P.O. Box 157  
Bristol, VT 05443  
802/453-4960

Insurance  
Accepted

No Charge for  
Phone Consultation

**David M. Ross, ACSW**

Certified Clinical Social Worker  
Individual, Couples & Group Therapy  
Deeply Respectful

Bollan House  
96 South Union Street  
Burlington, Vt. 05401  
&  
105 Hill St., Barre, Vt. 05641

(802) 862-3101

(802) 479-2115